CRP and retinal disorder: Clinical trials of anti-inflammatory or CRP-lowering therapies (for instance, IL-6 receptor antagonists, statins, or novel CRP inhibitors) with DR endpoints would test whether dampening systemic inflammation can slow retinopathy.